---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-200760"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-09-11T23:59:59+00:00"
generated_at: "2026-05-17T06:54:13.061867+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026

## Summary
- Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.
- Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.
- Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.
- Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.
- Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital.

## SEC filing metadata
- accession: 0001193125-25-200760
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/d90404d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-200760
- JSON: https://secwatch.observer/filing/0001193125-25-200760.json
- Plain text: https://secwatch.observer/filing/0001193125-25-200760.txt

## Key facts
- Equity Issuances
  Maze Therapeutics, Inc. issued up to an aggregate of 5,231,090 shares of Common Stock of warrant to certain institutional and accredited investors for $16.249 per Pre-Funded Warrant.
  - Security: warrant
  - Shares: up to an aggregate of 5,231,090 shares of Common Stock
  - Purchaser: certain institutional and accredited investors
  - Consideration: $16.249 per Pre-Funded Warrant
  source text: Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm
- Equity Issuances
  Maze Therapeutics, Inc. issued 4,000,002 shares of common stock to certain institutional and accredited investors for $16.25 per share.
  - Security: common stock
  - Shares: 4,000,002 shares
  - Purchaser: certain institutional and accredited investors
  - Consideration: $16.25 per share
  source text: Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312525200760/0001193125-25-200760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.